Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1208-1214

  Pizzorno, Andrés ^a   Abed, Yacine ^a   Bouhy, Xavier ^a   Beaulieu, Édith ^b   Mallett, Corey ^b   Russell, Rupert ^c   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

^b GLAXOSMITHKLINE   (Canada)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HISTIDINE; ISOLEUCINE; OSELTAMIVIR; PERAMIVIR; TYROSINE; VALINE; VIRUS SIALIDASE; ZANAMIVIR;

ANIMAL CELL; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL STRAIN; FERRET; FLUOROMETRY; GENE MUTATION; IC 50; INFLUENZA VIRUS A H1N1; MALE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVERSE GENETICS; SITE DIRECTED MUTAGENESIS; STRAIN DIFFERENCE; VIRUS GENE; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYCLOPENTANES; DOGS; DRUG RESISTANCE, VIRAL; FERRETS; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; MALE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PANDEMICS; REVERSE GENETICS; VIRAL PROTEINS; VIRUS REPLICATION; ZANAMIVIR;

EID: 84857159099     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05994-11     Document Type: Article

References (38)

1. Abed Y, Baz M, Boivin G. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11:971-976. (Pubitemid 44955172)
2. Abed Y, Simon P, Boivin G. 2010. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob. Agents Chemother. 54:2819-2822.
3. Baz M, Abed Y, McDonald J, Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43:1555-1561. (Pubitemid 44901897)
4. Baz M, et al. 2009. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N. Engl. J. Med. 361:2296-2297.
5. BioCryst Pharmaceuticals Inc. 27 October 2010, posting date. BioCryst's partner Shionogi receives approval for pediatric use of peramivir in Japan. http://investor.shareholder.com/biocryst/releasedetail.cfm?releaseid=523371.
6. Birnkrant D, Cox E. 2009. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N. Engl. J. Med. 361:2204-2207.
7. Centers for Disease Control and Prevention. 2009. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. Morb. Mortal. Wkly. Rep. 58:969-972.
8. Colman PM, Hoyne PA, Lawrence MC. 1993. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67:2972-2980. (Pubitemid 23143664)
9. Daiichi Sankyo Company Ltd. 10 September 2010, posting date. Daiichi Sankyo receives approval to manufacture and market Inavir® influenza antiviral inhalant for treatment in Japan. http://www.daiichisankyo.com/news/ 20100910-Inavir%20Release-ENG-final.pdf.
10. Davies BE. 2010. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother. 65(Suppl. 2):ii5-ii10.
11. Eshaghi A, et al. 2011. Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg. Infect. Dis. 17:1472-1474.
12. Hamelin ME, et al. 2010. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog. 6:e1001015.
13. Hamelin ME, et al. 2011. Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets. Antivir. Ther. 16:775-779.
14. Hatakeyama S, et al. 2005. Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J. Clin. Microbiol. 43:4139-4146. (Pubitemid 41129710)
15. Herlocher ML, et al. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630. (Pubitemid 39411012)
16. Hurt AC, Holien JK, Barr IG. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53:4433-4440.
17. Itoh Y, et al. 2009. In vitro and in vivo characterization of new swineorigin H1N1 influenza viruses. Nature 460:1021-1025.
18. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47(Pt 2):110-119.
19. Le Goff A, et al. 2010. Emergence of cross-resistance to oseltamivir and zanamivir in pandemic influenza A (H1N1) 2009 virus, abstr. V-448d. 50th Intersci. Conf. Antimicrob. Agents Chemother., 12 to 15 September 2010, Boston, MA.
20. Liu Q, et al. 2009. Improved and simplified recombineering approach for influenza virus reverse genetics. J. Mol. Genet. Med. 3:225-231.
21. Maines TR, et al. 2009. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325:484-487.
22. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. 2010. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin. Infect. Dis. 50:1252-1255.
23. Mishin VP, Hayden FG, Gubareva LV. 2005. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49:4515-4520. (Pubitemid 41552580)
24. Moscona A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-1373. (Pubitemid 41362704)
25. 50 data analysis. http://www.nisn.org/v-analysis-guidance-ic50.php. Accessed November 2011.
26. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. 2010. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Infect. Dis. 51:983-984.
27. Pizzorno A, Abed Y, Boivin G. 2011. Influenza drug resistance. Semin. Respir. Crit. Care Med. 32:409-422.
28. Pizzorno A, Bouhy X, Abed Y, Boivin G. 2011. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 203:25-31.
29. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha- D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296. (Pubitemid 9173017)
30. Shelton MJ, et al. 2011. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob. Agents Chemother. 55:5178-5184.
31. Sheu TG, et al. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292.
32. Simon P, et al. 2011. The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J. Clin. Microbiol. 49:715-717.
33. Takeshi N, Kitano M, Kodama M, Yoshida R, Sato A. 2011. Therapeutic effect of peramivir (BCX-1812) after single intravenous infusion in mice infected with influenza virus with H274Y mutated NA, abstr. VI-PO35-27. XV IUMS Int. Congr. Virol., 11 to 16 September 2011, Sapporo, Japan.
34. van der Vries E, Stelma FF, Boucher CA. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363:1381-1382.
35. van der Vries E, et al. 2011. Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog. 7:e1002276.
36. Wang Z, Tai CY, Mendel DB. 2000. Characterization of an influenza A virus variant selected in vitro in the presence of the neuraminidase inhibitor GS4071. Antiviral Res. 46:A60.
37. World Health Organization. 7 September 2011, posting date. Weekly update on oseltamivir resistance in influenza A(H1N1)2009 viruses. World Health Organization, Geneva, Switzerland. http://www.who.int /influenza/surveillance- monitoring/updates/2011-09-09-weekly-web -update-oseltamivir-resistance.pdf.
38. Yen HL, et al. 2006. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 80: 8787-8795.